Conference
-
Celanese to Join Fireside Chat at Deutsche Bank’s 16th Annual Global Industrials and Materials Conference
Celanese Corporation (CE) will participate in the Deutsche Bank Global Industrials and Materials Conference. President and CEO Scott Richardson will present a fireside chat on June 5, 2025, at 11:50 AM ET. A live webcast and replay (available for a year) will be accessible on the Celanese Investor Relations website. Celanese is a global specialty materials and chemicals leader, employing over 11,000 people and with $10.3 billion in 2024 net sales.
-
Cronos Group Inc. to Present at TD Cowen’s 9th Annual Future of the Consumer Conference
Cronos Group Inc. announced CEO Mike Gorenstein will present at the TD Cowen Future of the Consumer Conference on June 4, 2025. The company, focused on cannabinoid innovation with brands like Spinach and Lord Jones, aims to shape the consumer experience through research and development. The live webcast will be available on Cronos’ investor relations website. This release includes forward-looking statements.
-
Sprouts Farmers Market to Present at the Deutsche Bank Global Consumer Conference in 2025
Sprouts Farmers Market (SFM) announced its participation in the Deutsche Bank Global Consumer Conference in Paris. CEO Jack Sinclair and CFO Curtis Valentine will present at a fireside chat on June 4, 2025. A live webcast and replay will be available on the company’s website. Sprouts is a fast-growing specialty grocer committed to natural and organic foods.
-
Coya Therapeutics to Present at H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company developing Treg-targeted therapies for neuroinflammatory diseases, will headline H.C. Wainwright’s BioConnect Conference in New York City on May 16, 2025. CEO Dr. Arun Swaminathan will discuss the integration of its proprietary platforms, including lead compound COYA 302—a dual-pathway subcutaneous treatment combining LD IL-2 and CTLA4-Ig to address neuroinflammation. The company emphasizes its platforms’ potential in neurodegenerative, autoimmune, and metabolic disorders, while noting risks related to clinical timelines, regulation, and capital intensity in SEC filings. A live stream of the conference session will be available on its investor relations page for 90 days.